3β-azido-21-acetoxy-5β-pregnan-11β,17~-diol-20-one | 149916-69-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β-azido-21-acetoxy-5β-pregnan-11β,17~-diol-20-one
• 英文别名: 3β-azido-5β-pregnan-11β,17α,21-triol-20-one-21-acetate；3β-azido-21-acetoxy-5β-pregnan-11β, 17α-diol-20-one；[2-[(3S,5R,8S,9S,10S,11S,13S,14S,17R)-3-azido-11,17-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
• CAS: 149916-69-8
• 化学式: C₂₃H₃₅N₃O₅
• 分子量: 433.548
• InChiKey: WBEHCGFSGDZBRF-JYVMGGJNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  98.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3β-azido-21-acetoxy-5β-pregnan-11β,17~-diol-20-one 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 23.0 ℃ 、101.33 kPa 条件下， 反应 2.0h， 生成
  参考文献：
  名称：

  US2005/239760

  摘要：

  公开号：

文献信息

• Angiostatic steroids
  申请人：Alcon Laboratories, Inc.

  公开号：EP1236471A2

  公开（公告）日：2002-09-04

  Angiostatic steroids for use in controlling neovascularization and ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating neovascularization and ocular hypertension, including controlling the ocular hypertension associated with primary open angle glaucoma, are disclosed. In addition, the combination of the compounds with glucocorticoids for the prevention of elevated intraocular pressure during the treatment of inflammation is disclosed.

  本研究公开了用于控制新生血管和眼压的血管收缩类固醇。本发明公开了血管收缩类固醇的药物组合物及其用于治疗新生血管和眼压升高（包括控制与原发性开角型青光眼相关的眼压升高）的方法。此外，还公开了这些化合物与糖皮质激素的组合，用于在治疗炎症期间预防眼压升高。
• Sustained release eye drop formulations
  申请人：Ramscor, Inc.

  公开号：US10744202B2

  公开（公告）日：2020-08-18

  This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably α-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.

  本发明提供了生物相容性、可生物降解的滴眼液药物制剂，可用于治疗眼部疾病。特别是，生育酚及其低水溶性酯类，尤其是 α-生育酚乙酸酯，是生物相容性、无刺激性、可持续释放活性剂的外用眼药水制剂的理想载体。
• Multiphase gel
  申请人：BVW Holding AG

  公开号：US10668190B2

  公开（公告）日：2020-06-02

  Disclosed are hydrogels polymerized with or around a solid biofunctional moiety, biodegradable or permanent, designed to be implantable in a mammalian body, intended to block or mitigate the formation of tissue adhesions, and intended to aid in functional healing. The hydrogels of the present invention are characterized by comprising multiphasic structural elements: a) at least one gel phase, b) at least one solid phase, c) optional polymeric chains connecting gel and solid phases, d) optional shape designs that provide for an interpenetrating geometry between gels and solids, e) optional shape designs that enhance a tissue-hydrogel interface, and f) optional shape designs that provide a biofunctional aspect. The hydrophobicity of the various phases is chosen to reduce tissue adhesion and enhance tissue healing. The morphology of the polymers comprising the gel phase is typically of high molecular weight and has morphology that encourages entanglement. Useful polymeric structures include branching chains, comb or brush, and dendritic morphologies.

  本发明公开了与固体生物功能分子聚合或围绕固体生物功能分子聚合的水凝胶，可生物降解或永久性，可植入哺乳动物体内，用于阻断或减轻组织粘连的形成，并有助于功能性愈合。本发明水凝胶的特点是包含多相结构元素：a) 至少一个凝胶相；b) 至少一个固相；c) 连接凝胶和固相的任选聚合物链；d) 提供凝胶和固体之间相互渗透几何形状的任选形状设计；e) 增强组织-水凝胶界面的任选形状设计；f) 提供生物功能方面的任选形状设计。选择各种相的疏水性是为了减少组织粘附性并促进组织愈合。构成凝胶相的聚合物形态通常具有高分子量，并具有促进缠结的形态。有用的聚合物结构包括分支链、梳状或刷状以及树枝状形态。
• Angiostatic agents and methods and compositions for controlling ocular hypertension
  申请人：Bingaman P. David

  公开号：US20050239760A1

  公开（公告）日：2005-10-27

  Compositions of angiostatic agents for treating choroidal neovascularization resulting from ocular surgery or from trauma to ocular tissue and methods for their use are disclosed.

  本研究公开了用于治疗眼部手术或眼部组织创伤导致的脉络膜新生血管的血管抑制剂组合物及其使用方法。
• ANGIOSTATIC STEROIDS
  申请人：ALCON LABORATORIES, INC.

  公开号：EP0614463B1

  公开（公告）日：2003-02-12